<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(4)</volume><submitter>Rohrbeck A</submitter><pubmed_abstract>Clostridium botulinum exoenzyme C3 is the prototype of C3-like ADP-ribosyltransferases that modify the GTPases RhoA, B, and C. C3 catalyzes the transfer of an ADP-ribose moiety from the co-substrate nicotinamide adenine dinucleotide (NAD) to asparagine-41 of Rho-GTPases. Although C3 does not possess cell-binding/-translocation domains, C3 is able to efficiently enter intact cells, including neuronal and macrophage-like cells. Conventionally, the detection of C3 uptake into cells is carried out via the gel-shift assay of modified RhoA. Since this gel-shift assay does not always provide clear, evaluable results an additional method to confirm the ADP-ribosylation of RhoA is necessary. Therefore, a new monoclonal antibody has been generated that specifically detects ADP-ribosylated RhoA/B, but not RhoC, in Western blot and immunohistochemical assay. The scFv antibody fragment was selected by phage display using the human naive antibody gene libraries HAL9/10. Subsequently, the antibody was produced as scFv-Fc and was found to be as sensitive as a commercially available RhoA antibody providing reproducible and specific results. We demonstrate that this specific antibody can be successfully applied for the analysis of ADP-ribosylated RhoA/B in C3-treated Chinese hamster ovary (CHO) and HT22 cells. Moreover, ADP-ribosylation of RhoA was detected within 10 min in C3-treated CHO wild-type cells, indicative of C3 cell entry.</pubmed_abstract><journal>Toxins</journal><pagination>100</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4848626</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Detection and Quantification of ADP-Ribosylated RhoA/B by Monoclonal Antibody.</pubmed_title><pmcid>PMC4848626</pmcid><pubmed_authors>Hagemann S</pubmed_authors><pubmed_authors>Vu XK</pubmed_authors><pubmed_authors>Pich A</pubmed_authors><pubmed_authors>Rohrbeck A</pubmed_authors><pubmed_authors>Hust M</pubmed_authors><pubmed_authors>Just I</pubmed_authors><pubmed_authors>Fuhner V</pubmed_authors><pubmed_authors>Berndt S</pubmed_authors><pubmed_authors>Schroder A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Detection and Quantification of ADP-Ribosylated RhoA/B by Monoclonal Antibody.</name><description>Clostridium botulinum exoenzyme C3 is the prototype of C3-like ADP-ribosyltransferases that modify the GTPases RhoA, B, and C. C3 catalyzes the transfer of an ADP-ribose moiety from the co-substrate nicotinamide adenine dinucleotide (NAD) to asparagine-41 of Rho-GTPases. Although C3 does not possess cell-binding/-translocation domains, C3 is able to efficiently enter intact cells, including neuronal and macrophage-like cells. Conventionally, the detection of C3 uptake into cells is carried out via the gel-shift assay of modified RhoA. Since this gel-shift assay does not always provide clear, evaluable results an additional method to confirm the ADP-ribosylation of RhoA is necessary. Therefore, a new monoclonal antibody has been generated that specifically detects ADP-ribosylated RhoA/B, but not RhoC, in Western blot and immunohistochemical assay. The scFv antibody fragment was selected by phage display using the human naive antibody gene libraries HAL9/10. Subsequently, the antibody was produced as scFv-Fc and was found to be as sensitive as a commercially available RhoA antibody providing reproducible and specific results. We demonstrate that this specific antibody can be successfully applied for the analysis of ADP-ribosylated RhoA/B in C3-treated Chinese hamster ovary (CHO) and HT22 cells. Moreover, ADP-ribosylation of RhoA was detected within 10 min in C3-treated CHO wild-type cells, indicative of C3 cell entry.</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Apr</publication><modification>2025-06-01T12:01:23.041Z</modification><creation>2019-06-06T15:45:21Z</creation></dates><accession>S-EPMC4848626</accession><cross_references><pubmed>27043630</pubmed><doi>10.3390/toxins8040100</doi></cross_references></HashMap>